Maintaining research and development (R&D) productivity at a sustainable level is one of
the main challenges currently facing the pharmaceutical industry. In this article, we discuss …

In 2011, AstraZeneca embarked on a major revision of its research and development (R&D)
strategy with the aim of improving R&D productivity, which was below industry averages in …

The topic of R&D productivity in the pharmaceutical industry has been discussed for more
than 20 years. It has been largely a story of decline. In fact, around 90% of potential drugs …

Background Studies on the early 2000s documented increasing attrition rates and duration
of clinical trials, leading to a representation of a “productivity crisis” in pharmaceutical …

For the past 20 years target-based drug discovery has been the main research paradigm
used by the pharmaceutical industry and billions of dollars have been invested into this …

The pharmaceutical industry is under growing pressure from a range of environmental
issues, including major losses of revenue owing to patent expirations, increasingly cost …

The productivity of the pharmaceutical industry has been widely discussed in recent years,
particularly with regard to concerns that substantial expenditures on research and …

Over the past 30 years process R&D functions within the pharmaceutical industry have
undergone a remarkable transformation. At one time the bulk of investment of time and …

Drug development projects have high attrition rates, often because efficacy and safety
issues have not been foreseen. More effective prediction of'translational success' could …

The transformation of drug discovery in the past decade will result in an expanding array of
novel development candidates that will outstrip the development resources of even the …